XTX Topco Ltd Acquires Shares of 6,351 Insulet Co. (NASDAQ:PODD)

XTX Topco Ltd bought a new stake in Insulet Co. (NASDAQ:PODD - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,351 shares of the medical instruments supplier's stock, valued at approximately $1,478,000.

Other hedge funds have also made changes to their positions in the company. Integrated Wealth Concepts LLC grew its position in Insulet by 1.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock worth $596,000 after acquiring an additional 42 shares during the period. Glenmede Trust Co. NA lifted its stake in shares of Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock valued at $484,000 after purchasing an additional 47 shares during the last quarter. Wedmont Private Capital grew its holdings in shares of Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after purchasing an additional 48 shares during the period. OVERSEA CHINESE BANKING Corp Ltd raised its holdings in Insulet by 4.7% in the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier's stock valued at $250,000 after buying an additional 48 shares during the period. Finally, Blue Trust Inc. lifted its position in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 58 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. BTIG Research lifted their price target on shares of Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Piper Sandler upped their price target on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 17th. Morgan Stanley lifted their price objective on Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. Barclays raised their target price on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a report on Monday, November 11th. Finally, Canaccord Genuity Group boosted their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a "buy" rating in a research note on Monday. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $255.60.

Insulet Stock Down 0.1 %

Shares of PODD traded down $0.34 during midday trading on Monday, reaching $265.12. The stock had a trading volume of 437,164 shares, compared to its average volume of 763,980. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company's fifty day simple moving average is $247.48 and its two-hundred day simple moving average is $217.32. The company has a market cap of $18.60 billion, a price-to-earnings ratio of 45.46, a PEG ratio of 4.06 and a beta of 1.21. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.